Primers used in this study. by Hadi Alizadeh (20854757)

“…<div><p>Ovarian cancer therapy remains a challenge for human health, partly due to chemotherapy resistance. …”

Raw Gel. by Techit Thavorasak (13138440)

“…These findings highlight the potential of SmpB as a novel antimicrobial target, offering a promising strategy to weaken bacterial virulence without promoting resistance. Targeting the trans-translation system may pave the way for innovative therapies against multidrug-resistant <i><i>A. baumannii</i></i>.…”

Trial design. by Llum Páez (22553360)

“…Vaccination against canine leishmaniasis intends to decrease the parasite burden and the risk of clinical disease. …”

Schedule of the trial. by Llum Páez (22553360)

“…Vaccination against canine leishmaniasis intends to decrease the parasite burden and the risk of clinical disease. …”

Clinical symptoms scoring system. by Llum Páez (22553360)

“…Vaccination against canine leishmaniasis intends to decrease the parasite burden and the risk of clinical disease. …”

Marketed vaccines against canine leishmaniasis. by Llum Páez (22553360)

“…Vaccination against canine leishmaniasis intends to decrease the parasite burden and the risk of clinical disease. …”

Self-paced combined training alleviated oxidative stress, inflammatory responses and hyperlipidaemia in people living with multiple sclerosis: a randomised controlled trial by Sonda Jallouli (20484146)

“…</p> <p></p><p>12-week combined training was a safe therapy for people living multiple sclerosis.</p><p>Combined high-intensity interval training and resistance training (HIIT-RT) alleviated oxidative stress and inflammation.…”

Table 1_Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations.docx by Bhavana Bhatnagar (11016429)

“…<p>Acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) experience shorter disease-free survival and high relapse rates even with FLT3 inhibitor therapy. One of the main mechanisms for loss of response is the acquisition of molecular mutations that confer drug resistance to FLT3 inhibitors. …”

Data Sheet 1_Isoform-specific vs. pan-histone deacetylase inhibition as approaches for countering glioblastoma: an in vitro study.docx by Ameya Joshi (1290186)

“…The non-specific inhibitor Vorinostat surprisingly promoted migration in the cells at its 2D IC50 value treatment, and none of the inhibitors was able to significantly decrease late resistance compared to untreated controls, indicating the need for the development of more potent HDAC inhibitors for monotherapy for GBM.…”

Table 3_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 7_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Image 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.jpg by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 8_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 4_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 6_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 2_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Image 2_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.jpg by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 5_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Data Sheet 1_Efficacy of cartilage-targeted IGF-1 in a mouse model of growth hormone insensitivity.docx by Krishma Tailor (13730582)

“…Here, we studied CV1574-1 in a second mouse model, C57BL/6 wild-type mice treated with pegvisomant to induce GH resistance. In this model, once-daily injections of CV1574-1 for 5 days partially restored the pegvisomant-induced decrease in growth plate height without increasing kidney cell proliferation. …”